Disclosed are an organic proton-type ionic liquid, a film with a two-dimensional perovskite pure-phase quantum well structure, a preparation method and use thereof. The chemical formula of the organic proton-type alkylamine acetate ionic liquid is RNH.sub.3.sup.+—RCOO.sup.−, where R represents an alkyl group of C4-8 or a phenyl group, preferably, the chemical formula of the organic proton-type alkylamine acetate ionic liquid is CH.sub.3(CH.sub.2).sub.3NH.sub.3.sup.+—CH.sub.2COO.sup.−. The organic proton-type alkylamino acetate ionic liquid disclosed in the present disclosure can be used to prepare perovskite material, the prepared perovskite film thereby can form a pure-phase single quantum well, and the crystal grain size of the film can reach the level of micrometers or even millimeters.

Disclosed are an organic proton-type ionic liquid, a film with a two-dimensional perovskite pure-phase quantum well structure, a preparation method and use thereof. The chemical formula of the organic proton-type alkylamine acetate ionic liquid is RNH.sub.3.sup.+—RCOO.sup.−, where R represents an alkyl group of C4-8 or a phenyl group, preferably, the chemical formula of the organic proton-type alkylamine acetate ionic liquid is CH.sub.3(CH.sub.2).sub.3NH.sub.3.sup.+—CH.sub.2COO.sup.−. The organic proton-type alkylamino acetate ionic liquid disclosed in the present disclosure can be used to prepare perovskite material, the prepared perovskite film thereby can form a pure-phase single quantum well, and the crystal grain size of the film can reach the level of micrometers or even millimeters.

Provided are ion channel antagonists/blockers and uses thereof. Specifically, it provides the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details. Provided is also pharmaceutical composition useful for treatment of heart disease and other ion channel related diseases.

##STR00001##

Proposed is a catalyst complex having high activity for carbon dioxide conversion reaction that converts carbon dioxide to useful compounds through reaction of carbon dioxide and hydrocarbon containing at least one hydroxyl group, and a carbon dioxide conversion process using the same, wherein the catalyst complex includes, as an active metal in the catalyst complex, at least one of noble metals and at least one of transition metals other than noble metals, thereby having high activity for the carbon dioxide conversion reaction.

Proposed is a catalyst complex having high activity for carbon dioxide conversion reaction that converts carbon dioxide to useful compounds through reaction of carbon dioxide and hydrocarbon containing at least one hydroxyl group, and a carbon dioxide conversion process using the same, wherein the catalyst complex includes, as an active metal in the catalyst complex, at least one of noble metals and at least one of transition metals other than noble metals, thereby having high activity for the carbon dioxide conversion reaction.

The concerns a process for producing formic acid, (a) a carbon capture step in which a source of carbon dioxide is contacted with an amine solution in an amine scrubber, to obtain an ammonium bicarbonate solution, where the carbon capture uses a chilled amine solution having a temperature in the range of 0-20 ° C.; (b) inducing crystallization in the ammonium bicarbonate solution to obtain a concentrated ammonium bicarbonate solution; (c) subjecting the concentrated ammonium bicarbonate solution to a hydrogenation step to obtain an ammonium formate; and (d) heating the ammonium formate to a temperature in the range of 50-150 ° C., to obtain a gaseous product containing the amine and a liquid product stream containing formic acid. The application further concerns a system for performing the process.

The concerns a process for producing formic acid, (a) a carbon capture step in which a source of carbon dioxide is contacted with an amine solution in an amine scrubber, to obtain an ammonium bicarbonate solution, where the carbon capture uses a chilled amine solution having a temperature in the range of 0-20 ° C.; (b) inducing crystallization in the ammonium bicarbonate solution to obtain a concentrated ammonium bicarbonate solution; (c) subjecting the concentrated ammonium bicarbonate solution to a hydrogenation step to obtain an ammonium formate; and (d) heating the ammonium formate to a temperature in the range of 50-150 ° C., to obtain a gaseous product containing the amine and a liquid product stream containing formic acid. The application further concerns a system for performing the process.

A benzodiazepine compound represented by formula I, or a salt thereof has an intravenous sedative anesthesia effect. The recovery quality of the compound is significantly improved compared with remimazolam in rat and mouse caudal venous anesthesia models. During anesthetization, the compound has a rapid onset, a short duration, a quick recovery and a good tolerance, can be used for anesthesia induction, anesthesia maintenance and day surgery anesthesia.

##STR00001##

The disclosure relates to oral formulations for gastric delivery of a pharmaceutically acceptable salt of a phenyl pyrrole aminoguanidine compound.

The present invention relates to a formate production method including: a first step of producing a formate by causing a reaction between carbon dioxide and hydrogen in a solution containing a solvent, a catalyst dissolved in the solvent, and a metal salt or an organic salt; and a second step of separating, by a separation membrane, the catalyst from a reaction solution obtained in the first step, in which the catalyst contains at least one metal element selected from the group consisting of metal elements belonging to Group 8, Group 9, and Group 10 of a periodic table.